Published in J Immunol on October 01, 1985
Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"? Clin Microbiol Rev (2000) 1.26
Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J Exp Med (1986) 1.21
Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal. Immunol Rev (2016) 0.78
Neutrophils, from cradle to grave and beyond. Immunol Rev (2016) 0.75
Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) (2000) 7.17
Hyper-IgE syndrome with recurrent infections--an autosomal dominant multisystem disorder. N Engl J Med (1999) 5.82
Granulocyte chemotaxis: an improved in vitro assay employing 51 Cr-labeled granulocytes. J Immunol (1973) 4.61
Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) (2000) 4.45
The p47phox mouse knock-out model of chronic granulomatous disease. J Exp Med (1995) 4.25
The regulatory role of divalent cations in human granulocyte chemotaxis. Evidence for an association between calcium exchanges and microtubule assembly. J Cell Biol (1974) 4.10
Structural analysis of human neutrophil migration. Centriole, microtubule, and microfilament orientation and function during chemotaxis. J Cell Biol (1977) 3.33
Current concepts: immunology. Neutrophils in human diseases. N Engl J Med (1987) 3.29
Cloning of a 67-kD neutrophil oxidase factor with similarity to a noncatalytic region of p60c-src. Science (1990) 3.15
Evidence for distinct intracellular pools of receptors for C3b and C3bi in human neutrophils. J Immunol (1985) 3.02
Antibodies directed against synthetic peptides distinguish between GTP-binding proteins in neutrophil and brain. J Biol Chem (1987) 2.99
Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med (2001) 2.75
Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet (1999) 2.63
Role of secretory events in modulating human neutrophil chemotaxis. J Clin Invest (1978) 2.59
Kinetic analysis of chemotactic factor generation in human serum via activation of the classical and alternate complement pathways. Clin Immunol Immunopathol (1975) 2.56
Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: case report and review of occurrences in the Americas. Clin Infect Dis (1998) 2.53
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
The selective eosinophil chemotactic activity of histamine. J Exp Med (1975) 2.45
Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge. J Clin Invest (1975) 2.40
Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science (1989) 2.39
Histamine type I receptor occupancy increases endothelial cytosolic calcium, reduces F-actin, and promotes albumin diffusion across cultured endothelial monolayers. J Cell Biol (1986) 2.36
Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods (1995) 2.35
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N Engl J Med (1980) 2.32
Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med (1981) 2.31
Cytochrome b558: the flavin-binding component of the phagocyte NADPH oxidase. Science (1992) 2.31
Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med (2000) 2.26
Mechanism for the inflammatory response in primate lungs. Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest (1977) 2.24
The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood (2000) 2.24
Secretory responses of human neutrophils: exocytosis of specific (secondary) granules by human neutrophils during adherence in vitro and during exudation in vivo. J Immunol (1979) 2.20
Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med (1994) 2.07
Granulocyte function in the Chediak-Higashi syndrome of mice. Blood (1974) 2.04
Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) (1998) 2.03
Two forms of autosomal chronic granulomatous disease lack distinct neutrophil cytosol factors. Science (1988) 2.00
Immunologic reactivity of the lung: the in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages. Am Rev Respir Dis (1978) 1.97
Use of lipophilic probes of membrane potential to assess human neutrophil activation. Abnormality in chronic granulomatous disease. J Clin Invest (1980) 1.97
IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol (1990) 1.94
Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two cytosolic components of the NADPH oxidase system. N Engl J Med (1989) 1.93
Serum lipids in infection. N Engl J Med (1969) 1.93
Stimulation of neutrophil oxygen-dependent metabolism by human leukocytic pyrogen. J Clin Invest (1979) 1.85
Successful treatment of Paecilomyces varioti infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections. Clin Infect Dis (1992) 1.84
Separation and functional characterization of human neutrophil subpopulations. Blood (1978) 1.80
NIH conference. Recent advances in chronic granulomatous disease. Ann Intern Med (1983) 1.76
Interactions between antibiotics and human neutrophils in the killing of staphylococci. J Clin Invest (1981) 1.74
Degranulating stimuli increase the availability of receptors on human neutrophils for the chemoattractant f-met-leu-phe. J Immunol (1980) 1.74
Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J Clin Invest (1974) 1.69
Interaction of chemotactic factors with human macrophages. Induction of transmembrane potential changes. J Cell Biol (1977) 1.64
Microbicidal/cytotoxic proteins of neutrophils are deficient in two disorders: Chediak-Higashi syndrome and "specific" granule deficiency. J Clin Invest (1988) 1.63
Severe Burkholderia (Pseudomonas) gladioli infection in chronic granulomatous disease: report of two successfully treated cases. Clin Infect Dis (1995) 1.63
Human neutrophil-specific granule deficiency: a model to assess the role of neutrophil-specific granules in the evolution of the inflammatory response. Blood (1982) 1.62
Interaction of chemotactic factors with human polymorphonuclear leukocytes: studies using a membrane potential-sensitive cyanine dye. J Membr Biol (1980) 1.62
The differential mobilization of human neutrophil granules. Effects of phorbol myristate acetate and ionophore A23187. Am J Pathol (1977) 1.60
Correlation of human neutrophil secretion, chemoattractant receptor mobilization, and enhanced functional capacity. J Immunol (1982) 1.58
Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis (1990) 1.55
Spleen-derived mononuclear cell chemotactic factor in malaria infections: a possible mechanism for splenic macrophage accumulation. J Immunol (1977) 1.53
Trimethoprim-sulfamethoxazole prophylaxis in the management of chronic granulomatous disease. J Infect Dis (1990) 1.49
Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A (1997) 1.48
A functional differentiation of human neutrophil granules: generation of C5a by a specific (secondary) granule product and inactivation of C5a by azurophil (primary) granule products. J Immunol (1977) 1.47
The relationship between alloimmunization and posttransfusion granulocyte survival: experience in a chronic granulomatous disease cohort. Transfusion (2010) 1.45
Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. J Exp Med (1999) 1.44
Human immunodeficiency virus (HIV) infection in CD4+ T lymphocytes genetically deficient in LFA-1: LFA-1 is required for HIV-mediated cell fusion but not for viral transmission. J Exp Med (1991) 1.44
Exudation primes human and guinea pig neutrophils for subsequent responsiveness to the chemotactic peptide N-formylmethionylleucylphenylalanine and increases complement component C3bi receptor expression. J Clin Invest (1986) 1.41
Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest (1988) 1.41
Degranulating stimuli decrease the neagative surface charge and increase the adhesiveness of human neutrophils. J Clin Invest (1980) 1.41
Use of an X-linked human neutrophil marker to estimate timing of lyonization and size of the dividing stem cell pool. J Clin Invest (1985) 1.41
Essential requirement of cytosolic phospholipase A2 for activation of the phagocyte NADPH oxidase. J Biol Chem (1998) 1.39
Impairment of neutrophil bactericidal capacity in patients with AIDS. J Infect Dis (1988) 1.38
Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem (1990) 1.38
Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis Rheum (1976) 1.36
Unopsonized Candida albicans hyphae stimulate a neutrophil respiratory burst and a cytosolic calcium flux without membrane depolarization. J Infect Dis (1987) 1.36
Human neutrophil heterogeneity exists, but is it meaningful? Blood (1984) 1.35
Microfilaments in epidermal cancer cells. J Cell Biol (1974) 1.35
Immunochemical evidence for a novel pertussis toxin substrate in human neutrophils. J Biol Chem (1986) 1.33
Deactivation of human neutrophil chemotaxis by chemoattractants: effect on receptors for the chemotactic factor f-Met-Leu-Phe. J Immunol (1981) 1.33
Human neutrophils contain an intracellular pool of putative receptors for the chemoattractant N-formyl-methionyl-leucyl-phenylalanine. Blood (1983) 1.32
Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci U S A (1988) 1.31
Induction of T cell activation by monoclonal anti-Thy-1 antibodies. J Immunol (1986) 1.30
Agents that increase cyclic AMP inhibit accumulation of cGMP and depress human monocyte locomotion. J Immunol (1978) 1.29
The hyperimmunoglobulin E recurrent-infection (Job's) syndrome. A review of the NIH experience and the literature. Medicine (Baltimore) (1983) 1.28
Leucocyte chemotaxis: physiological considerations and abnormalities. Clin Haematol (1975) 1.28
Genetic demonstration of p47phox-dependent superoxide anion production in murine vascular smooth muscle cells. Circulation (2001) 1.28